← NEUROCRINE BIOSCIENCES INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $15.0m | $161.6m | $451.2m | $788.1m | $1.0b | $1.1b | $1.5b | $1.9b | $2.4b | $2.9b | |
| Cost of Revenue | $11.2m | $1.3m | $4.9m | $715.8m | $882.9m | $1.0b | $23.2m | $39.7m | $34.0m | $52.1m | |
| Gross Profit (Calculated) (derived) | $3.8m | $160.4m | $446.4m | $72.3m | $163.0m | $102.5m | $1.5b | $1.8b | $2.3b | $2.8b | |
| Operating Expenses | $162.4m | $293.0m | $414.3m | $715.8m | $882.9m | $1.0b | — | — | — | — | |
| Operating Income (Loss) | ($147.4m) | ($131.4m) | $36.9m | $72.3m | $163.0m | $102.5m | $249.0m | $250.9m | $570.5m | $619.1m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | — | — | — | — | — | — | $500k | $3.5m | $3.6m | $4.1m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | $218.0m | $409.2m | $597.5m | $845.2m | |
| Realized Investment Gains (Losses) | $0 | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | $21.8m | $46.5m | $106.7m | $101.4m | $213.9m | $332.1m | $486.0m | $705.4m | |
| Investment Income, Net | $2.8m | $6.2m | — | — | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Parent | ($141.1m) | ($142.5m) | $21.1m | $37.0m | $407.3m | $89.6m | $154.5m | $249.7m | $341.3m | $478.6m | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($141.1m) | ($142.5m) | $21.1m | $37.0m | $407.3m | $89.6m | $154.5m | $249.7m | $341.3m | $478.6m | |
| Earnings Per Share, Basic | ($1.63) | ($1.62) | $0.23 | $0.40 | $4.38 | $0.95 | $1.61 | $2.56 | $3.40 | $4.81 | |
| Earnings Per Share, Diluted | ($1.63) | ($1.62) | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 | |
| Weighted Average Number of Shares Outstanding, Basic | 86.7m | 88.1m | 90.2m | 91.6m | 93.1m | 94.6m | 95.8m | 97.7m | 100.4m | 99.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 86.7m | 88.1m | 95.4m | 95.7m | 97.8m | 97.9m | 98.9m | 101.0m | 103.7m | 102.5m | |
| Research and Development Expense | $94.3m | $121.8m | $160.5m | — | — | — | — | — | — | — | |
| General and Administrative Expense | $68.1m | — | — | — | — | — | — | — | — | — | |
| Selling, General and Administrative Expense | $68.1m | $169.9m | $248.9m | $354.1m | $433.3m | $583.3m | $752.7m | $887.6m | $1.0b | $1.2b | |
| Other Nonoperating Income (Expense) | $13k | ($20k) | — | — | — | — | — | — | — | — | |
| Costs and Expenses | — | — | — | — | — | — | $1.2b | $1.6b | $1.8b | $2.2b | |
| Current Income Tax Expense (Benefit) | — | — | $730k | $9.5m | $10.1m | $6.3m | $37.4m | $143.1m | $267.7m | $62.6m | |
| Interest Expense | — | $19.5m | $30.5m | $32.0m | $32.8m | $25.8m | $7.1m | $4.6m | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $730k | $9.5m | ($300.6m) | $11.8m | $59.4m | $82.4m | $144.7m | $226.8m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.